Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial / Iveson, Timothy J (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ; Kerr, Rachel S (Department of Oncology, University of Oxford, Oxford, UK) ; Saunders, Mark P (The Christie Hospital, Manchester, UK) ; Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Hollander, Niels Henrik (Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark) ; Tabernero, Josep (VHIO) ; Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ; Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ; Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ; Boyd, Kathleen Anne (Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK) ; Briggs, Andrew (Center for Health and Policy Outcomes, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre, Glasgow UK) ; Medley, Louise (Royal United Hospital, Bath, UK) ; Wilson, Charles (Addenbrookes Hospital, Cambridge, UK) ; Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ; Dhadda, Amandeep S (Castle Hill Hospital, Hull, UK) ; Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ; Olesen, Rene K (Department of Oncology, Aarhus University Hospital, Aarhus, Denmark) ; Propper, David (Barts Cancer Institute, Queen Mary University of London, London, UK) ; Bridgewater, John (UCL Cancer Institute, University College London, London UK) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ; Webb, Andrew (Brighton and Sussex University Hospital Trust, Brighton, UK) ; Cunningham, David (Royal Marsden Hospital, London, UK) ; Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ; Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S (Hammersmith Hospital, Imperial College London, London, UK) ; Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ; Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 - 10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578  
2.
7 p, 434.6 KB SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer / Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ; Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ; Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ; Iveson, Timothy (Southampton University Hospital NHS Foundation Trust) ; Kerr, Rachel S. (University of Oxford. Department of Oncology) ; Saunders, Mark P. (The Christie Hospital) ; Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Hollander, Niels Henrik (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ; Glimelius, Bengt (University of Uppsala) ; Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre) ; Medley, Louise (Royal United Hospital) ; Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ; Dhadda, Amandeep S. (Castle Hill Hospital) ; Hughes, Rob (Mount Vernon Cancer Centre) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (Southampton University Hospital NHS Foundation Trust) ; Olesen, Rene K (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Propper, David (Queen Mary, University of London. Barts Cancer Institute) ; Bridgewater, John (University College London) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ; Webb, Andrew (Brighton and Sussex University Hospital Trust) ; Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ; Hickish, Tamas (Poole Hospital/Bournemouth University) ; Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S (Hammersmith Hospital, Imperial College London) ; Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338  

Vea también: autores con nombres similares
1 Iveson, Timothy J
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.